IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer

被引：7
|
作者：
Huang, Chengliang [1 ,2 ]
Gan, Gregory N. [3 ,4 ]
Zhang, Jun [2 ,4 ]
机构：
[1] Southwest Med Univ, Affiliated Hosp, Dept Resp & Crit Care Med 2, 25 Taiping St, Luzhou 646000, Sichuan, Peoples R China
[2] Univ Kansas, Dept Internal Med, Div Med Oncol, Canc Ctr,Med Ctr, 3005 Wahl Hall East,3901 Rainbow Blvd, Kansas City, KS 66160 USA
[3] Univ Kansas, Dept Radiat Oncol, Canc Ctr, Med Ctr, 3005 Wahl Hall East,3901 Rainbow Blvd, Kansas City, KS 66160 USA
[4] Univ Kansas, Med Ctr, Canc Ctr, Dept Canc Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA
来源：
JOURNAL OF HEMATOLOGY & ONCOLOGY | 2020年 / 13卷 / 01期
关键词：
Extensive-stage small cell lung cancer; Immunotherapy; PD-1; PD-L1; Radiation therapy; CTLA-4; CD80; CD28; TIGIT; CD155 (PVR); EXPRESSION; PD-L1;
D O I：
10.1186/s13045-020-00898-y
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The life expectancy of extensive-stage small cell lung (ES-SCLC) cancer patients has not improved in the last 2-3 decades until two recent trials (CASPIAN and IMpower133) showing the addition of anti-programmed death ligand (PD-L1) therapy to chemotherapy has survival benefit over chemotherapy alone. However, such benefit is relatively small and was not even observed in some other trials using immunotherapy, raising the question of optimal chemoimmunotherapy combination in the 1st-line setting for ES-SCLC. Here, we discussed several thought-provoking questions with the focus on IMpower133 and CASPIAN trials.
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Prognostic value of baseline clinicopathological characteristics in first-line chemotherapy ± immunotherapy for extensive-stage small cell lung cancer: a retrospective cohort study
    Wu, Yili
    Ye, Jiankui
    Shao, Zhuowei
    Rossi, Antonio
    Chen, Yu
    Li, You
    Wu, Shibo
    JOURNAL OF THORACIC DISEASE, 2024, 16 (08) : 5348 - 5360
  • [22] The efficacy and safety of immunotherapy as first-line treatment for extensive-stage small cell lung cancer: evaluating based on reconstructed individual patient data
    Zhang, Shuang
    Li, Shuang
    Cheng, Ying
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [23] Local radiotherapy in extensive-stage small-cell lung cancer sustainably boosts the clinical benefit of first-line immunotherapy: a case report
    Wang, Hongming
    Wang, Nuoni
    Li, Shiyan
    Du, Yangfeng
    Wu, Tao
    Tian, Wei
    Dong, Wen
    Liu, Xiaoyang
    Zhang, Yan
    Zheng, Jiang
    Xiao, Zemin
    Wu, Zhijun
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [24] Immunotherapy improves survival in first-line treatment of extensive-stage small-cell lung cancer: A systematic review and meta-analysis
    Chan, Wei Yen
    Chin, Venessa
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 164 - 164
  • [25] Immunotherapy in first line for extensive-stage small-cell lung cancer: another piece is going to fill the puzzle?
    Passiglia, Francesco
    Novello, Silvia
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6
  • [26] A comparative study on etoposide combined with lobaplatin or cisplatin in the first-line treatment of extensive-stage small cell lung cancer
    Li, Shujun
    Liang, Yahai
    Wu, Yanxia
    Huang, Zhong
    Lin, Yanming
    Yang, Zhixiong
    Chen, Hualin
    Wu, Aibing
    JOURNAL OF BUON, 2020, 25 (03): : 1490 - 1496
  • [27] Dashing Decades of Defeat: Long Anticipated Advances in the First-line Treatment of Extensive-Stage Small Cell Lung Cancer
    Armstrong, Samantha A.
    Liu, Stephen, V
    CURRENT ONCOLOGY REPORTS, 2020, 22 (02)
  • [28] Prognostic Factors of First-Line Immune Checkpoint Inhibitors in Combination with Chemotherapy in Extensive-Stage Small Cell Lung Cancer
    Liao, Y. -T.
    Sun, R. -L.
    Huang, H. -C. H.
    Shen, C. -I.
    Tseng, Y. -H.
    Luo, Y. -H.
    Chen, Y. -M.
    Chiang, C. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S676 - S676
  • [29] Deep analysis of the trials and major challenges in the first-line treatment for patients with extensive-stage small cell lung cancer
    Gao, Ran
    Wu, Peizhu
    Yin, Xiaoyan
    Zhuang, Lulu
    Meng, Xiangjiao
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2025, 148
  • [30] Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer
    Liang, Xueyan
    Chen, Xiaoyu
    Li, Huijuan
    Li, Yan
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
12345